The impact of adenovirus infection on the immunocompromised host

Tsoline Kojaoghlanian, Phyllis Flomenberg, Marshall S. Horwitz

Research output: Contribution to journalArticle

237 Citations (Scopus)

Abstract

Adenovirus (Ad) infections in immunocompromised hosts have increased in frequency as the number of patients with transplants of bone marrow, liver, kidney, heart and other organs increase in number and survive longer. The numbers of such patients have also increased because of the emergence of the HIV epidemic. Ad infections with the 51 different serotypes recognised to date have few pathognomonic signs and symptoms, and thus require a variety of laboratory-based procedures to confirm infection. These viruses have the ability to target various organs with relative serotype specificity and can cause diverse manifestations including serious life-threatening diseases characteristic of the organs involved. Ads have cytolytic and immunoregulatory properties. The clinical dilemma remains the prompt recognition of Ad-related disease, the differentiation of Ad infection from Ad disease and the differentiation from other causative agents. Since the armamentarium of effective antiviral agents available to treat Ads is unproven by controlled trials and the virus is often not acquired de novo, it is difficult to prevent reactivation in immunodeficient hosts or new acquisition from donor organs. Timely discontinuation of immunosuppressive agents is necessary to prevent morbid outcomes. The clinical diseases, diagnostic tests, antiviral agents and biological aspects of the Ads as pathogens in immunocompromised patients are discussed in the context of this review. Some of the newer diagnostic tests are based on the well-studied molecular biology of Ads, which also have been attenuated by selective viral DNA deletions for use as vectors in numerous gene therapy trials in humans.

Original languageEnglish (US)
Pages (from-to)155-171
Number of pages17
JournalReviews in Medical Virology
Volume13
Issue number3
DOIs
StatePublished - May 2003
Externally publishedYes

Fingerprint

Adenoviridae Infections
Immunocompromised Host
Routine Diagnostic Tests
Adenoviridae
Antiviral Agents
Viruses
Viral DNA
Immunosuppressive Agents
Genetic Therapy
Signs and Symptoms
Molecular Biology
Bone Marrow
Tissue Donors
HIV
Transplants
Kidney
Liver
Infection
Serogroup

ASJC Scopus subject areas

  • Immunology

Cite this

The impact of adenovirus infection on the immunocompromised host. / Kojaoghlanian, Tsoline; Flomenberg, Phyllis; Horwitz, Marshall S.

In: Reviews in Medical Virology, Vol. 13, No. 3, 05.2003, p. 155-171.

Research output: Contribution to journalArticle

Kojaoghlanian, T, Flomenberg, P & Horwitz, MS 2003, 'The impact of adenovirus infection on the immunocompromised host', Reviews in Medical Virology, vol. 13, no. 3, pp. 155-171. https://doi.org/10.1002/rmv.386
Kojaoghlanian, Tsoline ; Flomenberg, Phyllis ; Horwitz, Marshall S. / The impact of adenovirus infection on the immunocompromised host. In: Reviews in Medical Virology. 2003 ; Vol. 13, No. 3. pp. 155-171.
@article{721a6de6e8af424eaa0e4e20fdc80117,
title = "The impact of adenovirus infection on the immunocompromised host",
abstract = "Adenovirus (Ad) infections in immunocompromised hosts have increased in frequency as the number of patients with transplants of bone marrow, liver, kidney, heart and other organs increase in number and survive longer. The numbers of such patients have also increased because of the emergence of the HIV epidemic. Ad infections with the 51 different serotypes recognised to date have few pathognomonic signs and symptoms, and thus require a variety of laboratory-based procedures to confirm infection. These viruses have the ability to target various organs with relative serotype specificity and can cause diverse manifestations including serious life-threatening diseases characteristic of the organs involved. Ads have cytolytic and immunoregulatory properties. The clinical dilemma remains the prompt recognition of Ad-related disease, the differentiation of Ad infection from Ad disease and the differentiation from other causative agents. Since the armamentarium of effective antiviral agents available to treat Ads is unproven by controlled trials and the virus is often not acquired de novo, it is difficult to prevent reactivation in immunodeficient hosts or new acquisition from donor organs. Timely discontinuation of immunosuppressive agents is necessary to prevent morbid outcomes. The clinical diseases, diagnostic tests, antiviral agents and biological aspects of the Ads as pathogens in immunocompromised patients are discussed in the context of this review. Some of the newer diagnostic tests are based on the well-studied molecular biology of Ads, which also have been attenuated by selective viral DNA deletions for use as vectors in numerous gene therapy trials in humans.",
author = "Tsoline Kojaoghlanian and Phyllis Flomenberg and Horwitz, {Marshall S.}",
year = "2003",
month = "5",
doi = "10.1002/rmv.386",
language = "English (US)",
volume = "13",
pages = "155--171",
journal = "Reviews in Medical Virology",
issn = "1052-9276",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - The impact of adenovirus infection on the immunocompromised host

AU - Kojaoghlanian, Tsoline

AU - Flomenberg, Phyllis

AU - Horwitz, Marshall S.

PY - 2003/5

Y1 - 2003/5

N2 - Adenovirus (Ad) infections in immunocompromised hosts have increased in frequency as the number of patients with transplants of bone marrow, liver, kidney, heart and other organs increase in number and survive longer. The numbers of such patients have also increased because of the emergence of the HIV epidemic. Ad infections with the 51 different serotypes recognised to date have few pathognomonic signs and symptoms, and thus require a variety of laboratory-based procedures to confirm infection. These viruses have the ability to target various organs with relative serotype specificity and can cause diverse manifestations including serious life-threatening diseases characteristic of the organs involved. Ads have cytolytic and immunoregulatory properties. The clinical dilemma remains the prompt recognition of Ad-related disease, the differentiation of Ad infection from Ad disease and the differentiation from other causative agents. Since the armamentarium of effective antiviral agents available to treat Ads is unproven by controlled trials and the virus is often not acquired de novo, it is difficult to prevent reactivation in immunodeficient hosts or new acquisition from donor organs. Timely discontinuation of immunosuppressive agents is necessary to prevent morbid outcomes. The clinical diseases, diagnostic tests, antiviral agents and biological aspects of the Ads as pathogens in immunocompromised patients are discussed in the context of this review. Some of the newer diagnostic tests are based on the well-studied molecular biology of Ads, which also have been attenuated by selective viral DNA deletions for use as vectors in numerous gene therapy trials in humans.

AB - Adenovirus (Ad) infections in immunocompromised hosts have increased in frequency as the number of patients with transplants of bone marrow, liver, kidney, heart and other organs increase in number and survive longer. The numbers of such patients have also increased because of the emergence of the HIV epidemic. Ad infections with the 51 different serotypes recognised to date have few pathognomonic signs and symptoms, and thus require a variety of laboratory-based procedures to confirm infection. These viruses have the ability to target various organs with relative serotype specificity and can cause diverse manifestations including serious life-threatening diseases characteristic of the organs involved. Ads have cytolytic and immunoregulatory properties. The clinical dilemma remains the prompt recognition of Ad-related disease, the differentiation of Ad infection from Ad disease and the differentiation from other causative agents. Since the armamentarium of effective antiviral agents available to treat Ads is unproven by controlled trials and the virus is often not acquired de novo, it is difficult to prevent reactivation in immunodeficient hosts or new acquisition from donor organs. Timely discontinuation of immunosuppressive agents is necessary to prevent morbid outcomes. The clinical diseases, diagnostic tests, antiviral agents and biological aspects of the Ads as pathogens in immunocompromised patients are discussed in the context of this review. Some of the newer diagnostic tests are based on the well-studied molecular biology of Ads, which also have been attenuated by selective viral DNA deletions for use as vectors in numerous gene therapy trials in humans.

UR - http://www.scopus.com/inward/record.url?scp=0038029587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038029587&partnerID=8YFLogxK

U2 - 10.1002/rmv.386

DO - 10.1002/rmv.386

M3 - Article

C2 - 12740831

AN - SCOPUS:0038029587

VL - 13

SP - 155

EP - 171

JO - Reviews in Medical Virology

JF - Reviews in Medical Virology

SN - 1052-9276

IS - 3

ER -